IRRAflow® system to be demonstrated at both CNS and EANS
tradeshows in October
STOCKHOLM, Oct. 3, 2018 /PRNewswire/ -- IRRAS AB ("IRRAS"),
a commercial-stage medical technology company focused on developing
and commercializing transformative treatments to manage
intracranial fluids, today announced that the company will be
participating in the Congress of Neurological Surgeons (CNS) 2018
Annual Meeting from October 6 – 10 in
Houston, TX, and the 18th EANS
European Congress of Neurosurgery from October 21 – 25 in Brussels, Belgium. These two meetings are key
forums for the latest research and technology in the world of
neurosurgery, and both attract attendees from all over the
world.
"Exhibiting at the CNS and EANS Congresses is an exciting next
step in the introduction of IRRAflow to the global
neurosurgery communities," stated Will
Martin, Chief Commercial Officer of IRRAS. "With our recent
US 510(k) clearance and eagerly anticipated CE mark
re-certification that will then allow us to conitnue sales in
Europe, we are ready to begin the
broader launch of our transformational technology at these
important events."
The IRRAflow system will be on display at CNS in IRRAS'
booth 917 and EANS in IRRAS' booth 14. To schedule a hands-on
demonstration of the IRRAflow system at either event, please
contact the company at info@irras.com.
For more information, please
contact:
US
Kleanthis G.
Xanthopoulos, Ph.D.
President & CEO
+1-800-213-4604
info@irras.com
Europe
Fredrik
Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
About IRRAS
IRRAS AB (NASDAQ First North Premier: IRRAS) is a
publicly-traded, commercial-stage medical technology company
focused on developing and commercializing innovative solutions for
brain surgery. The company's initial product, IRRAflow®,
addresses the complications associated with the current methods of
managing intracranial fluid by using a dual lumen catheter that
combines active irrigation with ongoing fluid drainage.
IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the IRRAflow catheter is
automatically flushed to prevent common catheter occlusions from
forming. Because IRRAflow is a completely closed system, it
is designed to reduce the documented infection risk of
these procedures. Additionally, IRRAflow incorporates ICP
monitoring and uses a proprietary software to regulate treatment
based on desired pressure levels.
With its unique product portfolio, protected by property patents
and patent applications, IRRAS is well positioned to establish a
leadership position in the medical device market. IRRAS maintains
its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco
is certified adviser of the company.
The information was released for public disclosure, through the
agency of the contact person above, on October 3 , 2018, at 8.30
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-to-participate-in-key-upcoming-neurosurgery-conferences,c2634005
The following files are available for download:
http://mb.cision.com/Main/16550/2634005/920129.pdf
|
Press release
(PDF)
|